Class I antiarrhythmic agents (quinidine or disopyramide) prevented the induction of sustained ventricular arrhythmias in all 5 patients with idiopathic ventricular fibrillation.
Case Report (n=5)
Do class I antiarrhythmic agents prevent the induction of ventricular arrhythmias and improve clinical outcomes in patients with idiopathic ventricular fibrillation?
In a small series of patients with idiopathic ventricular fibrillation, class I antiarrhythmic agents effectively prevented arrhythmia induction during electrophysiologic studies and were associated with a benign long-term clinical course.
Absolute Event Rate: 0% vs 100%
Ventricular fibrillation in patients without recognizable heart disease is uncommon and electrophysiologic data on such patients is limited. Over a 7 year period, five patients (three men and two women, ranging in age from 24 to 52 years) without demonstrable heart disease underwent electrophysiologic studies with pharmacologic drug testing because of single (four patients) or multiple (one patient) documented episodes of ventricular fibrillation. The arrhythmic event was unrelated to myocardial ischemia or infarction, metabolic or electrolyte disturbances, drug toxicity, preexcitation, or prolonged QT syndromes. In all three patients receiving no antiarrhythmic drugs and in two pretreated with amiodarone, a rapid poorly tolerated ventricular tachyarrhythmia requiring cardioversion was induced by programmed ventricular stimulation with up to two extrastimuli. In all instances, addition of either oral quinidine or oral disopyramide prevented the induction of sustained ventricular arrhythmias. All five patients were placed on antiarrhythmic drug regimens found effective during electrophysiologic studies and remained asymptomatic during follow-up periods ranging from 12 to 93 (mean 52) months. We conclude that in the patients with idiopathic ventricular fibrillation in our study: programmed ventricular stimulation reliably replicated the spontaneous arrhythmia, class I antiarrhythmic agents effectively prevented induction of the arrhythmia in the laboratory, and in contrast to the severity of the presenting arrhythmia, a benign clinical course was observed during long-term therapy with class I antiarrhythmic agents.
Belhassen et al. (Wed,) conducted a case report in Idiopathic ventricular fibrillation (n=5). Class I antiarrhythmic agents (oral quinidine or oral disopyramide) vs. Baseline (no antiarrhythmic drugs or amiodarone) was evaluated on Induction of sustained ventricular arrhythmias during programmed ventricular stimulation. Class I antiarrhythmic agents (quinidine or disopyramide) prevented the induction of sustained ventricular arrhythmias in all 5 patients with idiopathic ventricular fibrillation.